http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
-
Arrowhead licenses liver disease drug to Madrigal for $25 million upfront
-
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
-
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
-
Arrowhead receives Australia approval for rare disease drug REDEMPLO
-
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
-
ARWR receives positive EU opinion for REDEMPLO to treat rare genetic disorder
-
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
-
Arrowhead presents long-term plozasiran data for hypertriglyceridemia
-
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Sess
-
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
-
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
-
Arrowhead starts trial for dual-target RNAi drug ARO-DIMER-PA
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
-
Arrowhead receives China approval for rare disease drug REDEMPLO
-
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
-
Arrowhead Pharmaceuticals reports interim obesity drug trial results
-
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
-
Health Canada approves Arrowhead's REDEMPLO for rare triglyceride disorder
-
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
-
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals starts phase 1/2a trial for Alzheimer's drug
-
Arrowhead Pharmaceuticals begins Phase 1/2a trial of ARO-MAPT for Alzheimer's
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
-
Arrowhead gets FDA breakthrough therapy status for plozasiran drug
-
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
-
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
-
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
-
Arrowhead Pharmaceuticals receives $200 million from Sarepta milestone
-
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
-
FDA approves Arrowhead's REDEMPLO for rare triglyceride disorder
-
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
-
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
-
Arrowhead files application for dual-gene RNAi therapy trial
-
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
-
Arrowhead files lawsuit against Ionis over plozasiran patent dispute
-
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
-
Arrowhead Pharmaceuticals seeks approval for Alzheimer's drug trial
-
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
-
Arrowhead Pharmaceuticals partners with Novartis for $200 million deal
-
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
-
Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
-
Arrowhead receives $100 million milestone from Sarepta in mixed payment
-
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
